Literature DB >> 15908420

Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs.

A Williams1, N P Goonetilleke, H McShane, Simon O Clark, Graham Hatch, S C Gilbert, A V S Hill.   

Abstract

Tuberculosis is rising in the developing world due to poor health care, human immunodeficiency virus type 1 infection, and the low protective efficacy of the Mycobacterium bovis BCG vaccine. A new vaccination strategy that could protect adults in the developing world from tuberculosis could have a huge impact on public health. We show that BCG boosted by poxviruses expressing antigen 85A induced unprecedented 100% protection of guinea pigs from high-dose aerosol challenge with Mycobacterium tuberculosis, suggesting a strategy for enhancing and prolonging the efficacy of BCG.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15908420      PMCID： PMC1111825          DOI： 10.1128/IAI.73.6.3814-3816.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  12 in total

1.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.

Authors:  M A Horwitz; G Harth; B J Dillon; S Maslesa-Galic'
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis.

Authors:  C E Palmer; M W Long
Journal:  Am Rev Respir Dis       Date:  1966-10

3.  Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

Authors:  Helen McShane; Ansar A Pathan; Clare R Sander; Sheila M Keating; Sarah C Gilbert; Kris Huygen; Helen A Fletcher; Adrian V S Hill
Journal:  Nat Med       Date:  2004-10-24       Impact factor: 53.440

4.  BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies.

Authors:  Gillian F Black; Rosemary E Weir; Sian Floyd; Lyn Bliss; David K Warndorff; Amelia C Crampin; Bagrey Ngwira; Lifted Sichali; Bernadette Nazareth; Jenefer M Blackwell; Keith Branson; Steven D Chaguluka; Linda Donovan; Elizabeth Jarman; Elizabeth King; Paul E M Fine; Hazel M Dockrell
Journal:  Lancet       Date:  2002-04-20       Impact factor: 79.321

5.  BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life.

Authors:  P D Hart; I Sutherland
Journal:  Br Med J       Date:  1977-07-30

6.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.

Authors:  G A Colditz; T F Brewer; C S Berkey; M E Wilson; E Burdick; H V Fineberg; F Mosteller
Journal:  JAMA       Date:  1994-03-02       Impact factor: 56.272

7.  Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.

Authors:  Nilu P Goonetilleke; Helen McShane; Carolyn M Hannan; Richard J Anderson; Roger H Brookes; Adrian V S Hill
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

8.  Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.

Authors:  Samuel J McConkey; William H H Reece; Vasee S Moorthy; Daniel Webster; Susanna Dunachie; Geoff Butcher; Jenni M Vuola; Tom J Blanchard; Philip Gothard; Kate Watkins; Carolyn M Hannan; Simone Everaere; Karen Brown; Kent E Kester; James Cummings; Jackie Williams; D Gray Heppner; Ansar Pathan; Katie Flanagan; Nirmalan Arulanantham; Mark T M Roberts; Michael Roy; Geoffrey L Smith; Joerg Schneider; Tim Peto; Robert E Sinden; Sarah C Gilbert; Adrian V S Hill
Journal:  Nat Med       Date:  2003-05-25       Impact factor: 53.440

9.  Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

Authors:  Vasee S Moorthy; Egeruan B Imoukhuede; Sheila Keating; Margaret Pinder; Daniel Webster; Michael A Skinner; Sarah C Gilbert; Gijs Walraven; Adrian V S Hill
Journal:  J Infect Dis       Date:  2004-05-24       Impact factor: 5.226

10.  A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis.

Authors:  Marcus A Horwitz; Günter Harth
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441
View more
  45 in total

1.  Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing.

Authors:  S A Sharpe; H McShane; M J Dennis; R J Basaraba; F Gleeson; G Hall; A McIntyre; K Gooch; S Clark; N E R Beveridge; E Nuth; A White; A Marriott; S Dowall; A V S Hill; A Williams; P D Marsh
Journal:  Clin Vaccine Immunol       Date:  2010-06-09

2.  Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.

Authors:  Patricia A Darrah; Diane L Bolton; Andrew A Lackner; Deepak Kaushal; Pyone Pyone Aye; Smriti Mehra; James L Blanchard; Peter J Didier; Chad J Roy; Srinivas S Rao; David A Hokey; Charles A Scanga; Donata R Sizemore; Jerald C Sadoff; Mario Roederer; Robert A Seder
Journal:  J Immunol       Date:  2014-07-14       Impact factor: 5.422

Review 3.  Tuberculosis vaccines in clinical trials.

Authors:  Rosalind Rowland; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

Review 4.  Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis.

Authors:  Michael J Brennan; Bartholt Clagett; Hillary Fitzgerald; Vicki Chen; Ann Williams; Angelo A Izzo; Lewellys F Barker
Journal:  Vaccine       Date:  2012-03-03       Impact factor: 3.641

5.  Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.

Authors:  Dongmei Lu; Lucila Garcia-Contreras; Pavan Muttil; Danielle Padilla; Ding Xu; Jian Liu; Miriam Braunstein; David N McMurray; Anthony James Hickey
Journal:  AAPS J       Date:  2010-04-27       Impact factor: 4.009

6.  Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.

Authors:  Mark J Cayabyab; Birgit Korioth-Schmitz; Yue Sun; Angela Carville; Harikrishnan Balachandran; Ayako Miura; Kevin R Carlson; Adam P Buzby; Barton F Haynes; William R Jacobs; Norman L Letvin
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

7.  Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.

Authors:  Ming Zhang; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2016-12-14       Impact factor: 3.452

Review 8.  Immune mechanisms of protection: can adjuvants rise to the challenge?

Authors:  Amy S McKee; Megan K L MacLeod; John W Kappler; Philippa Marrack
Journal:  BMC Biol       Date:  2010-04-12       Impact factor: 7.431

9.  Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.

Authors:  Tony Hawkridge; Thomas J Scriba; Sebastian Gelderbloem; Erica Smit; Michele Tameris; Sizulu Moyo; Trudie Lang; Ashley Veldsman; Mark Hatherill; Linda van der Merwe; Helen A Fletcher; Hassan Mahomed; Adrian V S Hill; Willem A Hanekom; Gregory D Hussey; Helen McShane
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

10.  Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis.

Authors:  Zhou Xing; Christine T McFarland; Jean-Michel Sallenave; Angelo Izzo; Jun Wang; David N McMurray
Journal:  PLoS One       Date:  2009-06-10       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.